FDA Expands Approved Use of Regorafenib to Treat Liver Cancer

April 27, 2017 – The U.S. Food and Drug Administration today expanded the approved use of regorafinib to include treatment of patients with hepatocellular carcinoma (HCC or liver cancer) who have been previously treated with the drug sorafenib. This is the first FDA-approved treatment for a liver cancer in almost a decade. “Limited treatment options are available for patients with liver cancer,” said Richard Pazdur, M.D., acting director of the Office of Hematology and Oncology … (leggi tutto)